Principal Financial Group Inc Cassava Sciences Inc Transaction History

Principal Financial Group Inc

$162 Billion
Q1 2024

A detailed history of Principal Financial Group Inc transactions in Cassava Sciences Inc stock. As of the latest transaction made, Principal Financial Group Inc holds 10,965 shares of SAVA stock, worth $129,277. This represents 0.0% of its overall portfolio holdings.

Number of Shares

10,965

Previous 10,610 3.35%

Holding current value

$129,277

Previous $238,000 6.72%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 29, 2024	BUY	$18.44 - $26.41 $6,546 - $9,375	355 Added 3.35%	10,965 $222,000
Q4 2023 Feb 07, 2024	BUY	$12.64 - $30.11 $707 - $1,686	56 Added 0.53%	10,610 $238,000
Q3 2023 Nov 02, 2023	SELL	$16.64 - $25.32 $3,710 - $5,646	-223 Reduced 2.07%	10,554 $175,000
Q2 2023 Aug 07, 2023	BUY	$21.59 - $27.88 $16,775 - $21,662	777 Added 7.77%	10,777 $264,000
Q1 2023 May 09, 2023	SELL	$23.46 - $36.44 $17,688 - $27,475	-754 Reduced 7.01%	10,000 $241,000

Q4 2022 Feb 09, 2023	BUY	$27.82 - $44.16 $15,940 - $25,303	573 Added 5.63%	10,754 $317,000
Q3 2022 Nov 09, 2022	SELL	$16.33 - $51.06 $3,739 - $11,692	-229 Reduced 2.2%	10,181 $426,000
Q2 2022 Aug 10, 2022	SELL	$17.22 - $38.47 $1.57 Million - $3.5 Million	-90,948 Reduced 89.73%	10,410 $292,000
Q1 2022 May 09, 2022	SELL	$32.6 - $53.05 $1.44 Million - $2.34 Million	-44,180 Reduced 30.36%	101,358 $3.76 Million
Q4 2021 Feb 09, 2022	BUY	$36.77 - $90.91 $594,644 - $1.47 Million	16,172 Added 12.5%	145,538 $6.36 Million
Q3 2021 Nov 09, 2021	BUY	$41.79 - $135.3 $120,188 - $389,122	2,876 Added 2.27%	129,366 $8.03 Million
Q2 2021 Aug 10, 2021	BUY	$32.15 - $89.72 $3.92 Million - $10.9 Million	121,876 Added 2641.44%	126,490 $10.8 Million
Q1 2021 May 10, 2021	BUY	$7.09 - $87.95 $32,713 - $405,801	4,614 New	4,614 $207,000

Others Institutions Holding SAVA

# of Institutions

172

Shares Held

11.3M

Call Options Held

1.61M

Put Options Held

1.43M

View Full List

About CASSAVA SCIENCES INC

Ticker SAVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,097,900
Market Cap $473M
Description
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...

More about SAVA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Principal Financial Group Inc with notifications on news.

Account

Principal Financial Group Inc Cassava Sciences Inc Transaction History